Cartesian Therapeutics (RNAC) Competitors $11.33 +0.23 (+2.07%) Closing price 04:00 PM EasternExtended Trading$11.36 +0.03 (+0.22%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNAC vs. CDTX, ABCL, CVAC, CALT, NTLA, HROW, PRAX, AVDL, PAHC, and PHVSShould you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Cidara Therapeutics (CDTX), AbCellera Biologics (ABCL), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Intellia Therapeutics (NTLA), Harrow (HROW), Praxis Precision Medicines (PRAX), Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry. Cartesian Therapeutics vs. Its Competitors Cidara Therapeutics AbCellera Biologics CureVac Calliditas Therapeutics AB (publ) Intellia Therapeutics Harrow Praxis Precision Medicines Avadel Pharmaceuticals Phibro Animal Health Pharvaris Cidara Therapeutics (NASDAQ:CDTX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends. Do analysts prefer CDTX or RNAC? Cidara Therapeutics presently has a consensus price target of $64.14, suggesting a potential upside of 3.46%. Cartesian Therapeutics has a consensus price target of $40.00, suggesting a potential upside of 253.05%. Given Cartesian Therapeutics' higher possible upside, analysts plainly believe Cartesian Therapeutics is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Cartesian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more volatility & risk, CDTX or RNAC? Cidara Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.44, meaning that its share price is 56% less volatile than the S&P 500. Which has higher valuation and earnings, CDTX or RNAC? Cartesian Therapeutics has higher revenue and earnings than Cidara Therapeutics. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara Therapeutics$1.27M1,238.05-$169.83M-$11.13-5.57Cartesian Therapeutics$38.91M7.57-$77.42M-$52.83-0.21 Is CDTX or RNAC more profitable? Cartesian Therapeutics' return on equity of 0.00% beat Cidara Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -83.52% -61.76% Cartesian Therapeutics N/A N/A -6.19% Do insiders and institutionals hold more shares of CDTX or RNAC? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 87.0% of Cartesian Therapeutics shares are owned by institutional investors. 7.6% of Cidara Therapeutics shares are owned by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media refer more to CDTX or RNAC? In the previous week, Cidara Therapeutics had 15 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 20 mentions for Cidara Therapeutics and 5 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 1.01 beat Cidara Therapeutics' score of 0.94 indicating that Cartesian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCartesian Therapeutics beats Cidara Therapeutics on 9 of the 16 factors compared between the two stocks. Get Cartesian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNAC vs. The Competition Export to ExcelMetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$294.58M$3.03B$5.53B$9.82BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-0.2117.6930.0425.32Price / Sales7.57359.69446.31104.02Price / CashN/A40.7324.8128.01Price / Book-41.969.138.715.87Net Income-$77.42M-$54.75M$3.26B$265.10M7 Day Performance-4.23%-0.15%0.91%1.13%1 Month Performance-14.94%8.12%3.66%2.44%1 Year Performance-10.79%24.55%46.29%27.98% Cartesian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNACCartesian Therapeutics1.9406 of 5 stars$11.33+2.1%$40.00+253.0%-17.0%$294.58M$38.91M-0.2164Positive NewsEarnings ReportCDTXCidara Therapeutics3.4106 of 5 stars$62.46-0.7%$57.29-8.3%+425.0%$1.27B$1.27M-2.1290News CoverageEarnings ReportABCLAbCellera Biologics3.2311 of 5 stars$4.34+2.4%$8.75+101.6%+67.9%$1.27B$28.83M-7.75500Earnings ReportCVACCureVac3.9801 of 5 stars$5.46+0.9%$6.83+25.2%+65.5%$1.21B$579.18M5.93880Upcoming EarningsCALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180NTLAIntellia Therapeutics4.5814 of 5 stars$12.12+5.5%$33.37+175.3%-50.0%$1.19B$57.88M-2.32600Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionHROWHarrow2.5449 of 5 stars$33.42+7.0%$63.83+91.0%-6.1%$1.15B$199.61M-59.68180News CoverageEarnings ReportGap UpPRAXPraxis Precision Medicines1.6333 of 5 stars$51.09-5.5%$94.11+84.2%-11.5%$1.10B$8.55M-4.77110Analyst RevisionHigh Trading VolumeAVDLAvadel Pharmaceuticals2.5905 of 5 stars$11.26+1.6%$18.33+62.8%-17.5%$1.07B$169.12M-41.7070News CoveragePositive NewsEarnings ReportAnalyst UpgradeAnalyst RevisionPAHCPhibro Animal Health4.1777 of 5 stars$27.14+3.9%$24.40-10.1%+62.1%$1.06B$1.02B34.801,940PHVSPharvaris1.8619 of 5 stars$21.24+6.2%$36.20+70.4%+29.6%$1.05BN/A-7.0630News CoverageUpcoming Earnings Related Companies and Tools Related Companies CDTX Competitors ABCL Competitors CVAC Competitors CALT Competitors NTLA Competitors HROW Competitors PRAX Competitors AVDL Competitors PAHC Competitors PHVS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNAC) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredTurn your "dead money" into $306+ monthly (starting this month)Turn your "dead money" into $306+ monthly (starting this month) I've been tracking a financial revolution t...Investors Alley | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access